MedTrace Logo

Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

NCT03261206 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2025-05-20

No results posted yet for this study

Summary

The purpose of this study is to assess whether withdrawal of aminosalicylate (5-ASA) is non-inferior to continuation of 5-ASA therapy in Crohn's disease (CD) subjects in remission.

Conditions

  • Crohn Disease
  • Remission

Interventions

OTHER

5-ASA Withdrawal

Withdrawal of 5-ASA therapy

Sponsors & Collaborators

  • Academic Medical Organization of Southwestern Ontario

    collaborator OTHER

  • Alimentiv Inc.

    lead OTHER

Principal Investigators

  • Vipul Jairath, MD · Western University; London Health Sciences Centre

  • Gordon Moran, MD · University of Nottingham

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-20
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Canada
  • Italy
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03261206 on ClinicalTrials.gov